The Clinical Impact of Platelet Glycoprotein IIb/IIIa Receptor Blockade in Cardiovascular Medicine
Several of the adverse events that occur in acute coronary syndromes and after percutaneous coronary revascularization procedures are believed to be mediated by platelets. Recently, using molecular biology techniques, the platelet glycoprotein IIb/IIIa receptor was identified as the final common pat...
Gespeichert in:
| Veröffentlicht in: | JAPANESE CIRCULATION JOURNAL 1998, Vol.62(4), pp.233-243 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 243 |
|---|---|
| container_issue | 4 |
| container_start_page | 233 |
| container_title | JAPANESE CIRCULATION JOURNAL |
| container_volume | 62 |
| creator | Mak, Koon-Hou Tan, Arthur T. H. Chan, Charles Koh, Tian-Hai Topol, Eric J. |
| description | Several of the adverse events that occur in acute coronary syndromes and after percutaneous coronary revascularization procedures are believed to be mediated by platelets. Recently, using molecular biology techniques, the platelet glycoprotein IIb/IIIa receptor was identified as the final common pathway for platelet aggregation. Thus, blocking the action of this receptor would seem to be an attractive proposition for reducing ischemic complications. A monoclonal antibody was the first agent in this new pharmacological family to be designed, but several peptide and peptide-like substances have subsequently been developed. This paper reviews the development of this class of agents and the various preclinical and clinical trials that have been undertaken. Early studies evaluated such agents during percutaneous coronary revascularization procedures. Because of the overwhelming benefits observed in such patients, together with the current limitations of treatments for acute coronary syndromes, the scope of investigations has been extended. Preliminary reports have been encouraging. (Jpn Circ J 1998; 62: 233 - 243) |
| doi_str_mv | 10.1253/jcj.62.233 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79863324</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79863324</sourcerecordid><originalsourceid>FETCH-LOGICAL-c570t-8901167291866de9be3595dee151766026ef401199c2d0e1d037ca2e4869093c3</originalsourceid><addsrcrecordid>eNpFkM-LEzEUx4Moa129eBdyEA9Cu_kxyUxOokXXgRVF1nN4ffPGTU1nukkq7H9vpLVekgefD9-XfBl7KcVKKqOvtrhdWbVSWj9iC6mbdtl02j1mCyHqLDvVPWXPct4KodrGmAt24Uyn67Rgm9s74usYpoAQeb_bAxY-j_xbhEKRCr-ODzjv01woTLzvN1d93wP_Tkj7Mif-Ic74Cwbila4hDWH-DRkPERL_QkPAMNFz9mSEmOnF6b5kPz59vF1_Xt58ve7X72-WaFpRlp0TUtpWOdlZO5DbkDbODETSyNZaoSyNTVWcQzUIkoPQLYKiprNOOI36kr055tbX3h8oF78LGSlGmGg-ZN-6zmqtmiq-PYqY5pwTjX6fwg7Sg5fC_y3U10K9Vb4WWuVXp9TDZkfDWT01WPnrE6__hjgmmDDk_4nOWKlc1d4dtW0u8JPOHFIJGOnfxuZ41MVngneQPE36Dy1WkvU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79863324</pqid></control><display><type>article</type><title>The Clinical Impact of Platelet Glycoprotein IIb/IIIa Receptor Blockade in Cardiovascular Medicine</title><source>J-STAGE Free</source><source>MEDLINE</source><creator>Mak, Koon-Hou ; Tan, Arthur T. H. ; Chan, Charles ; Koh, Tian-Hai ; Topol, Eric J.</creator><creatorcontrib>Mak, Koon-Hou ; Tan, Arthur T. H. ; Chan, Charles ; Koh, Tian-Hai ; Topol, Eric J.</creatorcontrib><description>Several of the adverse events that occur in acute coronary syndromes and after percutaneous coronary revascularization procedures are believed to be mediated by platelets. Recently, using molecular biology techniques, the platelet glycoprotein IIb/IIIa receptor was identified as the final common pathway for platelet aggregation. Thus, blocking the action of this receptor would seem to be an attractive proposition for reducing ischemic complications. A monoclonal antibody was the first agent in this new pharmacological family to be designed, but several peptide and peptide-like substances have subsequently been developed. This paper reviews the development of this class of agents and the various preclinical and clinical trials that have been undertaken. Early studies evaluated such agents during percutaneous coronary revascularization procedures. Because of the overwhelming benefits observed in such patients, together with the current limitations of treatments for acute coronary syndromes, the scope of investigations has been extended. Preliminary reports have been encouraging. (Jpn Circ J 1998; 62: 233 - 243)</description><identifier>ISSN: 0047-1828</identifier><identifier>EISSN: 1347-4839</identifier><identifier>DOI: 10.1253/jcj.62.233</identifier><identifier>PMID: 9583455</identifier><identifier>CODEN: JCIRA2</identifier><language>eng</language><publisher>Kyoto: The Japanese Circulation Society</publisher><subject>Acute coronary syndrome ; Aspirin ; Biological and medical sciences ; Blood Platelets - physiology ; Blood. Blood coagulation. Reticuloendothelial system ; Clinical Trials as Topic ; Coronary Disease - blood ; Coronary Disease - drug therapy ; Coronary Disease - physiopathology ; Fibrinogen ; Humans ; Medical sciences ; Pharmacology. Drug treatments ; Platelet Aggregation Inhibitors - pharmacology ; Platelet Aggregation Inhibitors - therapeutic use ; Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors ; Platelet Glycoprotein GPIIb-IIIa Complex - physiology ; PTCA ; Vitronectin</subject><ispartof>JAPANESE CIRCULATION JOURNAL, 1998, Vol.62(4), pp.233-243</ispartof><rights>1998 THE JAPANESE CIRCULATION SOCIETY</rights><rights>1999 INIST-CNRS</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c570t-8901167291866de9be3595dee151766026ef401199c2d0e1d037ca2e4869093c3</citedby><cites>FETCH-LOGICAL-c570t-8901167291866de9be3595dee151766026ef401199c2d0e1d037ca2e4869093c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1881,4021,27921,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1956129$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9583455$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mak, Koon-Hou</creatorcontrib><creatorcontrib>Tan, Arthur T. H.</creatorcontrib><creatorcontrib>Chan, Charles</creatorcontrib><creatorcontrib>Koh, Tian-Hai</creatorcontrib><creatorcontrib>Topol, Eric J.</creatorcontrib><title>The Clinical Impact of Platelet Glycoprotein IIb/IIIa Receptor Blockade in Cardiovascular Medicine</title><title>JAPANESE CIRCULATION JOURNAL</title><addtitle>JAPANESE CIRCULATION JOURNAL</addtitle><description>Several of the adverse events that occur in acute coronary syndromes and after percutaneous coronary revascularization procedures are believed to be mediated by platelets. Recently, using molecular biology techniques, the platelet glycoprotein IIb/IIIa receptor was identified as the final common pathway for platelet aggregation. Thus, blocking the action of this receptor would seem to be an attractive proposition for reducing ischemic complications. A monoclonal antibody was the first agent in this new pharmacological family to be designed, but several peptide and peptide-like substances have subsequently been developed. This paper reviews the development of this class of agents and the various preclinical and clinical trials that have been undertaken. Early studies evaluated such agents during percutaneous coronary revascularization procedures. Because of the overwhelming benefits observed in such patients, together with the current limitations of treatments for acute coronary syndromes, the scope of investigations has been extended. Preliminary reports have been encouraging. (Jpn Circ J 1998; 62: 233 - 243)</description><subject>Acute coronary syndrome</subject><subject>Aspirin</subject><subject>Biological and medical sciences</subject><subject>Blood Platelets - physiology</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Clinical Trials as Topic</subject><subject>Coronary Disease - blood</subject><subject>Coronary Disease - drug therapy</subject><subject>Coronary Disease - physiopathology</subject><subject>Fibrinogen</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation Inhibitors - pharmacology</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - physiology</subject><subject>PTCA</subject><subject>Vitronectin</subject><issn>0047-1828</issn><issn>1347-4839</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkM-LEzEUx4Moa129eBdyEA9Cu_kxyUxOokXXgRVF1nN4ffPGTU1nukkq7H9vpLVekgefD9-XfBl7KcVKKqOvtrhdWbVSWj9iC6mbdtl02j1mCyHqLDvVPWXPct4KodrGmAt24Uyn67Rgm9s74usYpoAQeb_bAxY-j_xbhEKRCr-ODzjv01woTLzvN1d93wP_Tkj7Mif-Ic74Cwbila4hDWH-DRkPERL_QkPAMNFz9mSEmOnF6b5kPz59vF1_Xt58ve7X72-WaFpRlp0TUtpWOdlZO5DbkDbODETSyNZaoSyNTVWcQzUIkoPQLYKiprNOOI36kr055tbX3h8oF78LGSlGmGg-ZN-6zmqtmiq-PYqY5pwTjX6fwg7Sg5fC_y3U10K9Vb4WWuVXp9TDZkfDWT01WPnrE6__hjgmmDDk_4nOWKlc1d4dtW0u8JPOHFIJGOnfxuZ41MVngneQPE36Dy1WkvU</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>Mak, Koon-Hou</creator><creator>Tan, Arthur T. H.</creator><creator>Chan, Charles</creator><creator>Koh, Tian-Hai</creator><creator>Topol, Eric J.</creator><general>The Japanese Circulation Society</general><general>Japanese Circulation Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>1998</creationdate><title>The Clinical Impact of Platelet Glycoprotein IIb/IIIa Receptor Blockade in Cardiovascular Medicine</title><author>Mak, Koon-Hou ; Tan, Arthur T. H. ; Chan, Charles ; Koh, Tian-Hai ; Topol, Eric J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c570t-8901167291866de9be3595dee151766026ef401199c2d0e1d037ca2e4869093c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Acute coronary syndrome</topic><topic>Aspirin</topic><topic>Biological and medical sciences</topic><topic>Blood Platelets - physiology</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Clinical Trials as Topic</topic><topic>Coronary Disease - blood</topic><topic>Coronary Disease - drug therapy</topic><topic>Coronary Disease - physiopathology</topic><topic>Fibrinogen</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation Inhibitors - pharmacology</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - physiology</topic><topic>PTCA</topic><topic>Vitronectin</topic><toplevel>online_resources</toplevel><creatorcontrib>Mak, Koon-Hou</creatorcontrib><creatorcontrib>Tan, Arthur T. H.</creatorcontrib><creatorcontrib>Chan, Charles</creatorcontrib><creatorcontrib>Koh, Tian-Hai</creatorcontrib><creatorcontrib>Topol, Eric J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>JAPANESE CIRCULATION JOURNAL</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mak, Koon-Hou</au><au>Tan, Arthur T. H.</au><au>Chan, Charles</au><au>Koh, Tian-Hai</au><au>Topol, Eric J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Clinical Impact of Platelet Glycoprotein IIb/IIIa Receptor Blockade in Cardiovascular Medicine</atitle><jtitle>JAPANESE CIRCULATION JOURNAL</jtitle><addtitle>JAPANESE CIRCULATION JOURNAL</addtitle><date>1998</date><risdate>1998</risdate><volume>62</volume><issue>4</issue><spage>233</spage><epage>243</epage><pages>233-243</pages><issn>0047-1828</issn><eissn>1347-4839</eissn><coden>JCIRA2</coden><abstract>Several of the adverse events that occur in acute coronary syndromes and after percutaneous coronary revascularization procedures are believed to be mediated by platelets. Recently, using molecular biology techniques, the platelet glycoprotein IIb/IIIa receptor was identified as the final common pathway for platelet aggregation. Thus, blocking the action of this receptor would seem to be an attractive proposition for reducing ischemic complications. A monoclonal antibody was the first agent in this new pharmacological family to be designed, but several peptide and peptide-like substances have subsequently been developed. This paper reviews the development of this class of agents and the various preclinical and clinical trials that have been undertaken. Early studies evaluated such agents during percutaneous coronary revascularization procedures. Because of the overwhelming benefits observed in such patients, together with the current limitations of treatments for acute coronary syndromes, the scope of investigations has been extended. Preliminary reports have been encouraging. (Jpn Circ J 1998; 62: 233 - 243)</abstract><cop>Kyoto</cop><pub>The Japanese Circulation Society</pub><pmid>9583455</pmid><doi>10.1253/jcj.62.233</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0047-1828 |
| ispartof | JAPANESE CIRCULATION JOURNAL, 1998, Vol.62(4), pp.233-243 |
| issn | 0047-1828 1347-4839 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79863324 |
| source | J-STAGE Free; MEDLINE |
| subjects | Acute coronary syndrome Aspirin Biological and medical sciences Blood Platelets - physiology Blood. Blood coagulation. Reticuloendothelial system Clinical Trials as Topic Coronary Disease - blood Coronary Disease - drug therapy Coronary Disease - physiopathology Fibrinogen Humans Medical sciences Pharmacology. Drug treatments Platelet Aggregation Inhibitors - pharmacology Platelet Aggregation Inhibitors - therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Platelet Glycoprotein GPIIb-IIIa Complex - physiology PTCA Vitronectin |
| title | The Clinical Impact of Platelet Glycoprotein IIb/IIIa Receptor Blockade in Cardiovascular Medicine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T07%3A37%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Clinical%20Impact%20of%20Platelet%20Glycoprotein%20IIb/IIIa%20Receptor%20Blockade%20in%20Cardiovascular%20Medicine&rft.jtitle=JAPANESE%20CIRCULATION%20JOURNAL&rft.au=Mak,%20Koon-Hou&rft.date=1998&rft.volume=62&rft.issue=4&rft.spage=233&rft.epage=243&rft.pages=233-243&rft.issn=0047-1828&rft.eissn=1347-4839&rft.coden=JCIRA2&rft_id=info:doi/10.1253/jcj.62.233&rft_dat=%3Cproquest_cross%3E79863324%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79863324&rft_id=info:pmid/9583455&rfr_iscdi=true |